News GSK and J&J lead in vaccines research – but pricing still an... GlaxoSmithKline and Johnson & Johnson are leading R&D investment in vaccines, and the field is producing the first ever vaccines for conditions such as Ebola and a range of deadly b
News J&J to work with Orthocell on new regenerative stem cell the... Multi-centre trial of Ortho-ATI technology planned for early 2017.
News Johnson & Johnson back in 'exclusive' talks to buy Actelion Deal expected to be worth around $30 billion.
News No US Remicade biosimilar until at least October Pfizer must wait until 180 day period ends, court fight ongoing.
Views & Analysis A history of Johnson & Johnson Set up by three brothers back in 1886, Johnson & Johnson continues to keep evolving
News Relief for AZ as Truqap hits the spot in prostate cancer After a disappointing result with Truqap in triple-negative breast cancer, AstraZeneca chalks up a win in prostate cancer
Sales & Marketing Coming soon: The Life Sciences Industry Report 2025 – insigh... Prepare for 2025 with pharmaphorum’s Life Sciences Report, featuring expert insights on AI in drug development, gene therapy, and top industry trends